European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Personalized Therapies for Atrial Fibrillation. A Translational Approach

Descripción del proyecto

Un grupo de jóvenes investigadores se está tomando a pecho la fibrilación auricular

El corazón está formado por cuatro cámaras que se contraen y relajan de forma coordinada para bombear la sangre. Su disfunción puede causar dificultad para respirar, mareo y fatiga en casos leves, e insuficiencia cardíaca en los casos más graves. En la fibrilación auricular, las dos cámaras superiores del corazón (las aurículas) laten de forma rápida e irregular, aumentando el riesgo de ictus y enfermedades relacionadas. Existen diversas causas posibles y establecer la específica para cada paciente es fundamental para la eficacia del tratamiento. PersonalizeAF está desarrollando nuevas tecnologías para la caracterización de la fibrilación auricular que se complementan con nuevas estrategias terapéuticas. La red común de formación académica y clínica tiene previsto ofrecer terapias personalizadas y unos mejores desenlaces.

Objetivo

Atrial Fibrillation (AF) is the most common cardiac arrhythmia affecting more than 6 million Europeans with a cost exceeding 1% of the EU health care system budget (13.5 billion annually). New treatment strategies and the progress achieved in research on AF mechanisms and substrate evaluation methods to date have not been commensurate with an equivalent development of the knowledge and technologies required to individually characterize each patient in search of the most efficient therapy.

PersonalizeAF addresses this challenge by delivering an innovative multinational, multi-sectorial, and multidisciplinary research and training programme in new technologies and novel strategies for individualized characterization of AF substrate to and increase treatments’ efficiency.

From the research point of view, PersonalizeAF will integrate data and knowledge from in-vitro, in silico, ex vivo and in vivo animal and human models to: 1) generate an individual description of the state of the atrial muscle identifying the disease mechanisms and characteristics; 2) understanding the potential effect that different therapies have on different atrial substrates; and 3) combining this information to generate a specific profile of the patient and the best therapy for each patient.

With this purpose, PersonalizeAF partnership aggregates relevant scientific staff from the academic and clinical world with highly specialised biomedical companies which will be involved in a high-level personalised training programme that will train a new generation of highly skilled professionals and guarantee ESRs and future PhD students outstanding Career Opportunities in the biomedical engineering, cardiology services and medical devices sectors. PersonalizeAF will disseminate results to a wide spectrum of stakeholders, create awareness in the general public about atrial fibrillation and encourage vocational careers among young students.

Coordinador

UNIVERSITAT POLITECNICA DE VALENCIA
Aportación neta de la UEn
€ 501 809,76
Dirección
CAMINO DE VERA SN EDIFICIO 3A
46022 Valencia
España

Ver en el mapa

Región
Este Comunitat Valenciana Valencia/València
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 501 809,76

Participantes (12)